Business Context and Reporting Period
This Form 8-K filing by Graphite Bio, Inc. (GRPH) reports on events occurring between June 24, 2021, and June 29, 2021. The company, an emerging growth company incorporated in Delaware, announced the consummation of its Initial Public Offering (IPO) and related corporate governance amendments.
Key Financial Metrics
- Gross Proceeds: $273.7 million from the sale of 16,100,000 shares of common stock (14,000,000 initial shares plus 2,100,000 shares from the underwriters' option exercise).
- Offering Price: $17.00 per share.
- Net Proceeds: The filing states gross proceeds before deducting underwriting discounts, commissions, and estimated offering expenses; specific net proceeds are not provided in this text.
- Revenue, Profit, and Cash Flow: This filing does not provide operational financial metrics such as revenue, net income, operating cash flow, or margins.
- Debt and Liquidity: Specific debt levels and liquidity positions are not disclosed in this document.
Material Changes
The primary material change is the transition from a private to a public company via the IPO. Key structural changes include:
- Capital Structure: Authorization of 300,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock.
- Preferred Stock: Elimination of all references to previously existing series of preferred stock.
- Corporate Governance: Adoption of amended and restated bylaws that eliminate the ability of stockholders to take action by written consent or call special meetings, and establish specific procedures for stockholder proposals and director nominations.
Outlook, Risks, and Management Commentary
The filing confirms the closing of the IPO on June 29, 2021, and the expected closing of the additional shares on July 2, 2021. The company is now listed on The Nasdaq Global Market under the symbol "GRPH." The text does not contain specific forward-looking guidance, management commentary on future operations, or a detailed discussion of risks beyond the standard incorporation of the Underwriting Agreement and Registration Statement by reference.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses from the $273.7 million gross figure.
- Review the full Underwriting Agreement (Exhibit 1.1) for lock-up periods and indemnification terms.
- Confirm the exact number of shares outstanding post-IPO and the impact of the preferred stock conversion/elimination.
- Examine the Registration Statement (Form S-1) for detailed risk factors and use of proceeds not fully elaborated in this 8-K.